Rankings
▼
Calendar
CRBU Q3 2024 Earnings — Caribou Biosciences, Inc. Revenue & Financial Results | Market Cap Arena
CRBU
Caribou Biosciences, Inc.
$186M
Q3 2024 Earnings
Healthcare
Biotechnology
Income Statement
Revenue
$2M
-91.4% YoY
Gross Profit
$2M
100.0% margin
Operating Income
-$38M
-1889.2% margin
Net Income
-$35M
-1713.6% margin
EPS (Diluted)
$-0.38
QoQ Revenue Growth
-41.6%
Cash Flow
Operating Cash Flow
-$33M
Free Cash Flow
-$33M
Stock-Based Comp.
$4M
Balance Sheet
Total Assets
$344M
Total Liabilities
$63M
Stockholders' Equity
$281M
Cash & Equivalents
$32M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$2M
$24M
-91.4%
Gross Profit
$2M
-$5M
+141.1%
Operating Income
-$38M
-$15M
-161.3%
Net Income
-$35M
-$10M
-246.8%
Geographic Segments
UNITED STATES
$2M
82%
Non-US
$367,000
18%
← FY 2024
All Quarters
Q4 2024 →